- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03296917
Study Examining PrEP-001 in Subjects With Asthma
A Phase II, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Asthmatic Subjects Subsequently Challenged With Human Rhinovirus (HRV-16)
Study Overview
Detailed Description
Screening took place up to 90 days before quarantine, where volunteers were asked to complete an informed consent and undergo scheduled screening assessments to determine their eligibility.
Eligible volunteers were invited to test and record their respiratory symptoms and peak expiratory flow (PEF), medications and any adverse events in diary cards from Day -14 to Day -5.
They attended Quarantine on Day -4/-3, received the study drug/placebo intra nasally on Day -2 and Day -1 and subsequently challenged with HRV16 on Day 0. Randomisation to receive study drug/placebo was 1:1.
Volunteers remained in the quarantine unit for 8 days after inoculation.
PEF self-testing continued from Day 9 to Day 28.
On Day 20 (±3 days) and Day 28 (±5 days), volunteers attended follow up visits where they were assessed by a study physician for well-being, on-going symptoms and adverse events.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 to 55 years on the day of first dosing with IMP.
- Physician diagnosed asthma for at least 6 months prior to Screening and using treatment equivalent up to and including Global Initiative for Asthma (GINA) Stage 3.
- In good health with no history of major medical conditions (other than asthma) that will interfere with subject safety, as defined by medical history, physical examination, and routine laboratory tests as determined by the Investigator at a screening evaluation.
Exclusion Criteria:
- Any ex-smoker or smoker with a history of more than 10 pack-years.
- History of life-threatening asthma, Diagnosis of COPD as defined by the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014 guidelines.
- Any history or evidence of any clinically significant medical and psychiatric conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMP - PrEP-001
In Viral Challenge arm cohort: A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1). In the Safety arm's first dose cohort: A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1). Then assuming no significant safety issues with the lower dose (as determined by blinded review by the DSMB team), the Safety arm's second dose cohort will consist of: A nasal dose of 12800 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1) |
A spray dried powder for intranasal administration formulated from an aqueous mixture of pre-gelatinized waxy maize starch and the drug substance delivered using a single dose nasal powder device.
|
Placebo Comparator: Placebo - G-004
In the Viral Challenge arm and each Safety Arm cohort: A nasal dose of placebo equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1). |
A spray dried pre-gelatinized waxy maize starch powder (G-001) in the single dose nasal powder device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Efficacy Endpoint: The Area Under the Curve (AUC) of total symptom score post viral challenge.
Time Frame: Day -14 to Day 28
|
AUC of total symptom scores (upper respiratory tract (URT), lower respiratory tract (LRT) and systemic viral symptoms (SVS)).
Total symptom scores (from the symptom diary card) used to calculate the AUC.
The primary endpoint is only being derived from the Viral Challenge arm.
|
Day -14 to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Efficacy Endpoint: Symptom Scores: Area Under the Curve (AUC)
Time Frame: Day -4 to Day 28
|
AUC of individual symptom scores (upper respiratory tract (URT), lower respiratory tract (LRT) and systemic viral symptoms (SVS)).
A total symptom score is derived for each subject, separately for each assessment (symptom diary card) on each day.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Symptom Scores: Duration of symptoms
Time Frame: Day -4 to Day 28
|
Time (days).
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Symptom Scores: Peak symptoms score
Time Frame: Day -4 to Day 28
|
Numerical sum of all individual composite symptoms.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Symptom Scores: Time to peak symptoms
Time Frame: Day -4 to Day 28
|
Time (days).
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Symptom Scores: Time to resolution from peak symptoms
Time Frame: Day -4 to Day 28
|
Time (days).
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: viral shedding
Time Frame: Day -4 to Day 28
|
Number of subjects with viral shedding.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: incidence of laboratory-confirmed Influenza illness
Time Frame: Day -4 to Day 28
|
The number of subjects with laboratory-confirmed influenza infection.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: laboratory confirmed Influenza A/Perth/16/2009 (H3N2) Virus infection
Time Frame: Day -4 to Day 28
|
The number of subjects with laboratory-confirmed influenza A/Perth/16/2009 (H3N2) Virus infection.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: HRV-like-illness
Time Frame: Day -4 to Day 28
|
The number of subjects with HRV-like illness.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: Sub-clinical infection
Time Frame: Day -4 to Day 28
|
The number of subjects with Sub-clinical illness.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: Upper respiratory tract illness
Time Frame: Day -4 to Day 28
|
The number of subjects with Upper respiratory tract illness.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: Lower respiratory tract illness
Time Frame: Day -4 to Day 28
|
The number of subjects with Lower respiratory tract illness.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: Febrile illness
Time Frame: Day -4 to Day 28
|
The number of subjects with Febrile illness.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: Systemic illness
Time Frame: Day -4 to Day 28
|
The number of subjects with Systemic illness.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: Non-sick and uninfected
Time Frame: Day -4 to Day 28
|
The number of subjects Non-sick and uninfected.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: Viral replication, as measured by tissue culture assay
Time Frame: Day -4 to Day 28
|
The number of subjects with viral replication.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Incidence(s) of illness and infection: Seroconversion
Time Frame: Day -4 to Day 28
|
The number of subjects with seroconversion.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Viral Load Parameters: Area under the curve (AUC) of viral load, as measured by nasopharyngeal swab RT-qPCR
Time Frame: Day -4 to Day 28
|
Viral load data supplied in Log10 Copies/mL.
These values used to calculate the Area Under the Curve (AUC) for each subject.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Duration of virus shedding, as measured by nasal wash RT-qPCR
Time Frame: Day -4 to Day 28
|
Time (days).
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Peak virus shedding, as measured by nasal wash RT-qPCR
Time Frame: Day -4 to Day 28
|
The highest observed RT-qPCR viral load value.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Viral Load Parameters: Time to peak viral shedding, as measured by nasal wash RT-qPCR
Time Frame: Day -4 to Day 28
|
Time (days).
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Time to resolution from peak viral shedding, as measured by nasal wash RT-qPCR.
Time Frame: Day -4 to Day 28
|
Time (days).
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Area under the curve (AUC) of viral load, as measured by nasal wash TCID50.
Time Frame: Day -4 to Day 28
|
Tissue culture viral load data supplied in log10 TCID50/mL.
These values used to calculate the Area Under the Curve (AUC) for each subject.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Duration of virus shedding, as measured by nasal wash TCID50.
Time Frame: Day -4 to Day 28
|
Time (days).
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Peak virus shedding, as measured by nasal wash TCID50.
Time Frame: Day -4 to Day 28
|
The highest observed RT-qPCR viral load value.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Time to peak viral shedding, as measured by nasal wash TCID50.
Time Frame: Day -4 to Day 28
|
Time (days).
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Total weight of nasal discharge produced post Viral Challenge to Quarantine discharge.
Time Frame: Day -4 to Day 28
|
Weight (grams).
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Change in lung function compared to pre-Challenge.
Time Frame: Day -4 to Day 28
|
Peak Expiratory Flow (L/min) and FEV1 (L)
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Change in Asthma Control Questionnaire (ACQ) score compared to pre-Challenge.
Time Frame: Day -4 to Day 28
|
ACQ score.
|
Day -4 to Day 28
|
Secondary Efficacy Endpoint: Change in Fractional exhaled nitric oxide (FeNO) compared to pre-Challenge.
Time Frame: Day -4 to Day 28
|
FeNO (ppb).
|
Day -4 to Day 28
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory Efficacy Analysis: Proportion (on any occasion) of subjects with Grade 2 or worse symptoms at any day post-Viral Challenge.
Time Frame: Day -14 to Day 28
|
Number of subjects with Grade 2 or higher symptoms at any day post-Viral Challenge.
|
Day -14 to Day 28
|
Exploratory Efficacy Analysis: Proportion of subjects with Grade 2 or worse symptoms at each day post-Viral Challenge.
Time Frame: Day -4 to Day 28
|
Number of subjects with symptoms at Grade 2 or higher, at each day post-Viral Challenge.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Duration of Grade 2 or worse symptoms (post-Viral Challenge).
Time Frame: Day -4 to Day 28
|
Time (days).
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Proportion of subjects with any clinical symptoms (i.e., with Grade ≥ 1) (post-Viral Challenge).
Time Frame: Day -4 to Day 28
|
The proportion of subjects with symptoms grade 1 or higher.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Proportion of subjects with Grade ≥1 symptom score for upper respiratory tract (URT) symptoms (post-Viral Challenge).
Time Frame: Day -4 to Day 28
|
The proportion of subjects with upper respiratory tract symptoms.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Proportion of subjects with Grade ≥1 symptom score for lower respiratory tract (LRT) symptoms (post-Viral Challenge).
Time Frame: Day -4 to Day 28
|
The proportion of subjects with lower respiratory tract symptoms.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Proportion of subjects with Grade ≥1 symptom score for systemic symptoms (post-Viral Challenge).
Time Frame: Day -4 to Day 28
|
The proportion of subjects with systemic symptoms.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Time to peak for each reported and any symptoms (post-Viral Challenge).
Time Frame: Day -4 to Day 28
|
Time (days).
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Proportion of subjects with pyrexia.
Time Frame: Day -4 to Day 28
|
The proportion of subjects with pyrexia.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Duration of pyrexia.
Time Frame: Day -4 to Day 28
|
Time (hours).
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Tympanic temperature.
Time Frame: Day -4 to Day 28
|
Changes in tympanic temperature over time (post Viral Challenge) (degrees Celcius)
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Area under the curve (AUC) of symptom scores using the 13-item symptom diary card (total, URT, LRT and SVS), Day 1 (assessment 1) to Day 8.
Time Frame: Day -4 to Day 28
|
AUC of individual symptom scores.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Proportion of subjects with Lab-confirmed Clinical Symptoms of URTI.
Time Frame: Day -4 to Day 28
|
The number of subjects with lab-confirmed clinical symptoms of URTI.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Proportion of subjects with Lab-confirmed Clinical Symptoms of LRTI.
Time Frame: Day -4 to Day 28
|
The number of subjects with lab-confirmed clinical symptoms of LRTI.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Proportion of subjects with Lab-confirmed Clinical Symptoms of Systemic Illness (SI).
Time Frame: Day -4 to Day 28
|
The number of subjects with lab-confirmed clinical symptoms of SI.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Overall total symptom score, Day 1 (assessment 1) to Day 8, using the 10-item symptom diary card.
Time Frame: Day -4 to Day 28
|
Total symptom score.
|
Day -4 to Day 28
|
Exploratory Efficacy Analysis: Overall symptom scores (URT, LRT SVS), Day 1 (assessment 1) to Day 8, using the 10-item symptom diary card.
Time Frame: Day -4 to Day 28
|
Total symptom score.
|
Day -4 to Day 28
|
Safety endpoint: Treatment-emergent Adverse Events (TEAE).
Time Frame: Day -4 to Day 28
|
Incidence of treatment-emergent AEs (TEAE), overall, and by severity and causality (analysed descriptively).
|
Day -4 to Day 28
|
Safety endpoint: Clinical laboratory parameters.
Time Frame: Day -4 to Day 28
|
Absolute values and change from baseline in routine clinical laboratory parameters by timepoint (analysed descriptively).
Includes haematology, biochemistry, coagulation, cardiac enzymes, thyroid function tests and urinalysis parameters.
|
Day -4 to Day 28
|
Safety endpoint: Vital signs.
Time Frame: Day -4 to Day 28
|
Absolute values and change from baseline in vital signs parameters by timepoint (analysed descriptively); systolic blood pressure (SBP) (mmHg), diastolic blood pressure (DBP) (mmHg), respiratory rate (RR) (breaths per minute), heart rate (HR) (beats per minute) and SpO2 (%).
|
Day -4 to Day 28
|
Safety endpoint: Physical Examination.
Time Frame: Day -4 to Day 28
|
Physical examination findings (analysed descriptively).
|
Day -4 to Day 28
|
Safety endpoint: Spirometry.
Time Frame: Day -4 to Day 28
|
Absolute and changes from baseline for FEV1 [absolute] (L), FEV1 [% predicted] (%), FVC [absolute] (L), FVC [% predicted] (%), FEV1/FVC ratio [absolute], FEV1/FVC ratio [% predicted] (%), maximum mid expiratory flow (MMEF) [absolute] (L/sec) and MMEF [% predicted]).
The lung function parameter Peak Expiratory Flow [L/min] will also be summarised (analysed descriptively).
|
Day -4 to Day 28
|
Safety endpoint: ECGs.
Time Frame: Day -4 to Day 28
|
12-lead electrocardiogram (ECG) findings (analysed descriptively).
|
Day -4 to Day 28
|
Safety endpoint: Asthma Exacerbations (Number)
Time Frame: Day -4 to Day 28
|
Number and percentage of subjects experiencing any asthma exacerbations.
|
Day -4 to Day 28
|
Safety endpoint: Duration of each asthma exacerbation
Time Frame: Day -4 to Day 28
|
Time (days)
|
Day -4 to Day 28
|
Safety endpoint: Time to first asthma exacerbation
Time Frame: Day -4 to Day 28
|
Time (days)
|
Day -4 to Day 28
|
Safety endpoint: Subjects requiring treatment for asthma exacerbation
Time Frame: Day -4 to Day 28
|
Number of subjects requiring oral or parenteral steroids as treatment for their exacerbation.
|
Day -4 to Day 28
|
Safety endpoint: Subjects requiring hospitalisation for asthma exacerbation
Time Frame: Day -4 to Day 28
|
Number of subjects requiring hospitalisation for their exacerbation.
|
Day -4 to Day 28
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PrEP-CS-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Universita di VeronaCompleted
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on PrEP-001
-
HvivoPrep Biopharm LimitedCompleted
-
Prep Biopharm LimitedHvivoCompletedViral Upper Respiratory Tract InfectionUnited Kingdom
-
Prep Biopharm LimitedCompletedUpper Respiratory Tract InfectionsUnited Kingdom
-
University of UlsterNorthern Ireland Chest Heart and StrokeCompleted
-
Penn State UniversityRecruiting
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); Kenyatta National...Completed
-
San Diego State UniversityNational Institute of Mental Health (NIMH); Hennepin Healthcare Research InstituteCompleted
-
Hilary L Surratt, PhDNational Institute on Drug Abuse (NIDA)Active, not recruitingHIV PreventionUnited States
-
Montefiore Medical CenterNew York State Psychiatric InstituteActive, not recruiting
-
University of California, San FranciscoNational Institute of Nursing Research (NINR); San Francisco Department of...CompletedHIV/AIDSUnited States